| By Aesica Pharmaceuticals |
| Thursday, 10 September 2009 |
 |
Aesica Pharmaceuticals, an innovative supplier of contract development and manufacturing solutions,
has entered
|
into a new multi-year supply agreement with Amdipharm. Under the new contract Aesica will provide manufacturing and packaging services for several of Amdipharm’s leading products for supply to worldwide markets. Initially, the products covered include Erythrocin (erythromycin), Hytrin (terazosin), Loftyl (buflomedil), and the range is likely to expand in the future.
Manufacturing operations are carried out at Aesica’s finished dosage pharmaceutical production facility located in Queenborough, Kent. The award-winning site is equipped with extensive process technologies including capabilities for the manufacture of solid and liquid dosage forms, anaesthetics, controlled drugs; and facilities for packaging in blister packs, sachets and bottles. Aesica’s support to Amdipharm includes analytical, regulatory and supply chain services.
Amdipharm is an emerging global pharmaceutical enterprise and has its priority to supply essential prescription medicines to meet real clinical needs. Mick Cullen, Managing Director of Amdipharm Sales and Marketing Limited said: “We have been very pleased with our growing relationship with Aesica |
|
|
based on their reliability, flexibility and responsiveness.“ Mr. Adam Sims, Commercial Director of Aesica, said: “We have worked hard to ensure the smooth transfer of the new Amdipharm products into the Queenborough site. We are proud of our record of handling the complex multi-country supply and the wide range of product volumes”.
For more information please visit Aesica at CPhI,
Feria de Madrid (IFEMA),
October 13th - 15th,
Stand number 4B29, Hall 4,
or please contact:
Maria Koustareva,
Marketing Manager
T: +44 (0)191 218 1969
E:marketing@aesica-pharma.com
About Amdipharm:
Recognised for its young, dynamic and entrepreneurial personality, Amdipharm has garnered a significant level of growth and success since its inception in 2002 and is now widely considered a partner of choice with respect to both the acquisition and management of established brands. Already the company boasts a presence in over 100 countries and a portfolio of over 35 products. About Aesica:
Aesica is a leading supplier of Active Pharmaceutical Ingredients (APIs), formulated products and custom synthesis solutions to the |
|
global pharmaceutical and biotechnology industries. Aesica is a partner of choice to several of the top-ten pharmaceutical companies, leading generic manufacturers and emerging life science companies across the major pharmaceutical markets: Europe, North America and Japan.
Aesica has a well-balanced business model and takes a flexible commercial approach working with traditional fee-for-service agreements and also through strategic co-development partnerships with emerging companies.
Aesica has three state-of-the-art manufacturing facilities in the UK, which between them spread across more than 200 acres and employ over 700 people.
In September 2008 Aesica established a new US subsidiary, to drive further growth of its business after recent acquisitions of manufacturing sites from Merck Sharpe & Dohme and Abbott, and the move into the manufacture and packaging of finished dosage pharmaceutical products.
Want to read more?
Aesica Pharmaceutical Services Corporate Website
Aesica Pharmaceuticals - supplier of APIs, Formulations and Custom Synthesis Solutions
Aesica establishes US subsidiary to drive further growth in North America
|
|
|
